ADAR1 Capital Management »

Rapt Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Rapt Therapeutics (RAPT) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Rapt Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapt Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapt Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $186k 7.5k 24.85

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Rapt Therapeutics

T. Rowe Price Associates
Column Group
Perceptive Advisors
Vanguard Group
Dr. Jeffrey R. Jay, M.D.
Kingdon Capital Management
Samlyn Capital
Euclidean Capital
Alphabet
Cormorant Asset Management
Dimensional Fund Advisors
Millennium Management
Citadel Advisors
Braidwell
Redmile Group

View all funds holding Rapt Therapeutics